Evaluation of Relationship between Vitamin D Supplementation Treatment and Hypercalciuria in Patients with Kidney Stones

Background: Vitamin D, especially calcitriol (its active metabolite), increases gastrointestinal calcium absorption. Because urinary calcium excretion is associated with calcium absorption in the gastrointestinal tract; vitamin D metabolites could theoretically cause hypercalciuria. The aim of this study was to investigate the relationship between treatment and vitamin D supplementation on the rate of hypercalciuria in patients. Method: In the present double-blind randomized clinical trial, 90 patients (male-female) with urinary stones and serum vitamin D levels less than 30 ng/mL were evaluated. Patients were randomLy divided into two groups of 45 patients. One group was given 50,000 units of oral vitamin D weekly for up to 8 weeks. For the other group, the drug was given as a placebo for up to 8 weeks. Sampling was performed one month after the end of treatment. The data garnered from hospital records were inserted into SPSS software for analysis.Results: In the present study, the mean age of the subjects was 39.78 years. Also, out of 90 patients, 52 were male and 38 were female. Blood PTH levels decreased significantly after treatment in vitamin D group (P <0.001). Also, serum levels of vitamin D in this group showed a significant increase (P <0.001). However, in this study urinary calcium levels after treatment did not show significant changes (P = 0.680).Conclusion: The present study showed that in people with a history of kidney stones, taking vitamin D supplement alone for people with lower than standard serum levels of vitamin D did not show any significant difference in calcification. As a result, the therapeutic dose of this drug is recommended in patients with kidney stones according to the condition.